AbbVie Ventures and Lumination Capital joining existing lead investors Samsara BioCapital and Lightstone Ventures

艾伯维风投（AbbVie Ventures）和 Lumination Capital 加入现有领投方 Samsara BioCapital 和 Lightstone Ventures

Financing supports TNFα development candidate nomination and initiation of IND-enabling studies, alongside advancement of oral TL1A inhibitors into lead optimization

融资支持TNFα开发候选药物的提名及启动IND enabling研究，同时推进口服TL1A抑制剂进入先导化合物优化阶段

Proprietary QUAISAR platform, combined with approach to Physical AI, continues to drive rapid design of optimized oral drug candidates

专有的QUAISAR平台，结合物理人工智能方法，持续推动优化口服药物候选物的快速设计

WATERTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PsiThera, a biotechnology company harnessing biologically relevant protein states and physical artificial intelligence to create oral drugs for immune and inflammatory diseases, today announced the closing of a $25 million financing. New investors AbbVie Ventures and Lumination Capital participated, along with existing lead investors Samsara BioCapital and Lightstone Ventures, and other existing investors.

马萨诸塞州沃特敦，2026年11月10日（环球社电）——PsiThera是一家生物技术公司，致力于利用具有生物相关性的蛋白质状态和物理人工智能来开发用于免疫和炎症疾病的口服药物，今日宣布完成2500万美元的融资。新投资者艾伯维风投（AbbVie Ventures）和Lumination Capital参与投资，现有领投方Samsara BioCapital和Lightstone Ventures以及其他现有投资者也参与了本轮融资。

In connection with the financing, Claire Leurent, Ph.D., MBA, Managing Director at AbbVie Ventures, has joined PsiThera’s Board of Directors..

作为此次融资的一部分，艾伯维风投（AbbVie Ventures）的董事总经理克莱尔·勒伦特（Claire Leurent，哲学博士、工商管理硕士）已加入 PsiThera 公司董事会。

Proceeds from the financing are expected to fund operations, supporting development candidate nomination and the initiation of IND-enabling studies for the company’s lead oral small molecule TNFα inhibitor, as well as advancement of its oral TL1A program into lead optimization.

融资所得款项预计将用于运营资金，支持候选药物的提名，并启动公司主要口服小分子TNFα抑制剂的IND enabling研究，同时推进其口服TL1A项目进入先导化合物优化阶段。

The company’s proprietary QUAISAR platform combines physics-based molecular simulation, machine learning, and experimental biophysics into a single closed-loop discovery engine to design novel small molecule therapeutics more efficiently. QUAISAR models protein motion to identify and target transient binding pockets that conventional structure-based design cannot see, enabling the design of small molecules for targets that have been difficult to address with oral therapies.

该公司的专有 QUAISAR 平台将基于物理的分子模拟、机器学习和实验生物物理学整合为一个单一的闭环发现引擎，以更高效地设计新型小分子疗法。QUAISAR 对蛋白质运动进行建模，以识别并靶向传统基于结构的设计无法察觉的瞬态结合口袋，从而能够为那些难以通过口服疗法攻克的靶点设计小分子药物。

Using this platform, PsiThera advanced the company’s lead TNFα program from hit identification to lead optimization in just four months..

借助该平台，PsiThera 仅用四个月时间就将其领先的 TNFα 项目从苗头化合物识别推进至先导化合物优化阶段。

“Our goal is to bring the efficacy of leading biologics into novel oral medicines to improve on their therapeutic profiles. This financing accelerates our progress toward that vision as we advance our oral TNFα program toward development candidate nomination and clinical initiation and expand our pipeline of differentiated immunology therapeutics, starting with TL1A,” said Eric D.

“我们的目标是将领先生物制剂的疗效融入新型口服药物中，以优化其治疗特性。这笔融资加速了我们实现这一愿景的进程，因为我们正推进口服TNFα项目，朝着提名开发候选药物和启动临床试验迈进，并拓展我们差异化的免疫学治疗产品管线，首先从TL1A开始。”Eric D.表示。

Shaff, President and Chief Executive Officer of PsiThera. “We are grateful for the continued support of our existing investors and welcome AbbVie Ventures and Lumination Capital.”.

PsiThera 总裁兼首席执行官沙夫表示：“我们感谢现有投资者的持续支持，并欢迎艾伯维风险投资（AbbVie Ventures）和 Lumination Capital 的加入。”

Injectable anti-TNFα biologic therapies are approved across a broad range of immune-mediated diseases. However, an oral therapeutic could have broad application, both as monotherapy and as a combination partner, and provide an additional treatment option to the many patients who have not yet started biologic therapy..

注射型抗TNFα生物制剂疗法已在多种免疫介导疾病中获得批准。然而，口服疗法无论是作为单药治疗还是联合用药，都具有广泛的应用前景，并可为众多尚未开始生物制剂治疗的患者提供额外的治疗选择。

PsiThera’s oral TNFα inhibitors are designed to achieve a differentiated profile to improve the therapeutic index relative to injectables or other oral TNFα inhibitors in development, supporting best-in-class potential.

PsiThera的口服TNFα抑制剂旨在实现差异化的特性，以提高相对于注射剂或其他在研口服TNFα抑制剂的治疗指数，从而具备成为同类最佳药物的潜力。

“PsiThera has brought together seasoned biopharma leadership, experienced drug hunters, and immunology and computational scientists around a platform that can find and exploit protein states that conventional approaches cannot effectively drug,” said Christina Isacson, Ph.D., Chair of PsiThera’s Board of Directors and Partner at Lightstone Ventures.

“PsiThera 将经验丰富的生物制药领导者、资深药物研发专家以及免疫学和计算科学家汇聚在一起，围绕一个能够发现并利用传统方法难以有效靶向的蛋白质状态的平台展开工作，”PsiThera 董事会主席、Lightstone Ventures 合伙人 Christina Isacson 博士表示。

“Our progress with TNFα and TL1A is illustrative of the power of the platform. With this financing, the Company is well-positioned to advance its lead programs and extend its platform across a broader immunology pipeline.”.

“我们在TNFα和TL1A方面的进展彰显了该平台的强大实力。凭借此次融资，公司处于有利地位，能够推进其领先项目，并将平台扩展至更广泛的免疫学产品线。”

About PsiThera

关于 PsiThera

PsiThera is a biotechnology company harnessing biologically relevant protein states and physical artificial intelligence to create oral drugs for immune and inflammatory diseases, therapeutic areas historically reliant on injectables. By integrating biophysics, computational modeling, and mechanistic biology through its QUAISAR platform, PsiThera’s expert drug hunters discover new therapeutic opportunities and optimized drugs.

PsiThera 是一家生物技术公司，利用具有生物相关性的蛋白质状态和物理人工智能，为免疫性和炎症性疾病开发口服药物，而这些治疗领域历来依赖注射疗法。通过其 QUAISAR 平台整合生物物理学、计算建模和机制生物学，PsiThera 的资深药物研发专家能够发现新的治疗机会并优化药物设计。

The company’s initial programs target clinically validated cytokine pathways, including TNFα, TL1A, and IL-6. PsiThera is headquartered in Watertown, Massachusetts. For more information, please visit www.psithera.com or follow us on LinkedIn..

该公司的首批项目针对经临床验证的细胞因子通路，包括TNFα、TL1A和IL-6。PsiThera总部位于马萨诸塞州沃特敦。欲了解更多信息，请访问www.psithera.com或在LinkedIn上关注我们。

Investors:

投资者：

Carlo Tanzi, Ph.D.

卡洛·坦齐，博士

Kendall Investor Relations

肯德尔投资者关系

ctanzi@kendallir.com

ctanzi@kendallir.com

Media:

媒体：

Kotaro Yoshida

吉田光太郎

Argot Partners

阿戈特合伙人

kotaro@argotpartners.com

kotaro@argotpartners.com